Labopharm’s new antidepressant to be ‘game-changer’

It’s game on for Labopharm (TSX:DDS; NASDAQ:DDSS). By February 11, the FDA is expected to approve the company’s antidepressant trazodone, a novel once-daily formulation that addresses many of the shortcomings of similar drugs on the market.  “I think it’s fair to say this drug could be a game-changer for us,” CEO James Howard-Tripp says in [...]

Labopharm files tramadol-acetaminophen drug in Europe

Labopharm (TSX:DDS) has initiated the regulatory approval process for its twice-daily tramadol-acetaminophen formulation in Europe under a decentralized procedure (DCP) system. “Initiating the regulatory approval process in Europe builds on our recently established marketing partnership with Grenenthal GmbH,” Labopharm CEO James Howard-Tripp said in a statement. “It is our intention to commercialize our twice-daily tramadol-acetaminophen [...]